CinCor Pharma, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- CinCor Pharma, Inc. (NASDAQ: CINC) is a clinical-stage biopharmaceutical company focused on developing novel treatments for cardio-renal diseases, including resistant and uncontrolled hypertension, primary aldosteronism, and chronic kidney disease. The company, founded in 2018 and headquartered in Waltham, Massachusetts, advances baxdrostat (CIN-107), a highly selective oral small molecule inhibitor of aldosterone synthase targeting the enzyme responsible for aldosterone synthesis while sparing the cortisol pathway; it operates primarily in the United States with clinical trials evaluating baxdrostat across multiple indications such as treatment-resistant hypertension (Phase 2 BrigHTN trial topline data reported), uncontrolled hypertension (Phase 2 HALO trial), primary aldosteronism (ongoing Phase 2 Spark-PA trial), and chronic kidney disease (ongoing Phase 2 trial), with a Phase 3 trial planned for treatment-resistant hypertension. CinCor Pharma was spun out from CinRx Pharma, LLC in 2019; in February 2023, AstraZeneca completed its acquisition of CinCor for $1.3 billion upfront plus up to $500 million in contingent value rights tied to regulatory milestones, totaling approximately $1.8 billion, after which CinCor's shares were delisted from Nasdaq and it now operates as a subsidiary of AstraZeneca, bolstering the acquirer's cardiorenal pipeline with baxdrostat's potential for combination therapies.
Company News
There's a Lot to Love About Mineralys' Valentine's Day IPO
SHAREHOLDER ALERT: Weiss Law Investigates CinCor Pharma, Inc.
Why Is CinCor (CINC) Stock Up 138% Today?
AstraZeneca to acquire CinCor for US$1.8bn
AstraZeneca to Buy CinCor Pharma in $1.8 Billion Deal
AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln deal
These Were the 5 Best and Worst Performing Small-Cap Stocks in November 2022
CinCor (CINC) Tanks Due to Dismal Data on Hypertension Drug
CinCor's hypertension drug misses primary endpoint in mid-stage study
CinCor Pharma to Present at Upcoming Piper Sandler and Evercore ISI Investor Conferences
These Are the 10 Best-Performing IPOs in 2022 Through October
CinCor Pharma to Participate at Upcoming September Investor Conferences
7 No-Brainer Biotech Stocks to Add to Your Buy List
CinCor Pharma Begins Patient Dosing In Midstage Hypertension, Kidney Disease Study
CinCor Pharma to Present at the Jefferies Healthcare Conference
CinCor Pharma to Present at Upcoming Investor Conferences
CinCor Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 22, 2022
CinCor Pharma to Present at the 32nd Annual Oppenheimer Healthcare Conference
10 Best Stocks to Buy on the Nasdaq Right Now
U.S. IPO Weekly Recap: Biotechs Ring In The New Year In A 4 IPO Week